Sign up to save tools and stay up to date with the latest in AI
bg
bg
1

AI-Built Cancer Antibodies on the Horizon, Potentially Replacing Chemotherapy with AstraZeneca, Absci Collaboration

Dec 04, 2023 - techtimes.com
AstraZeneca and Absci have signed a deal worth approximately $247 million to work on Generative AI-Built Cancer Antibodies, aiming to replace chemotherapy. The partnership will utilize Absci's AI technology for large-scale protein analysis in the search for a viable cancer treatment. The companies are developing a zero-shot generative AI model to create novel and enhanced antibody therapies, with milestone payments, research and development financing, an upfront fee for Absci, and royalties on any product sales included in the agreement.

AstraZeneca's goal of creating AI-assisted cancer antibodies aligns with its recently announced aim of replacing chemotherapy. The company has shown in clinical studies that its novel treatment outperforms traditional chemotherapy. The partnership with Absci is seen as an exciting opportunity to use AI for antibody production, with AI helping to find more and better biologics faster. Absci's CEO, Sean McClain, stated that using engineering concepts in drug discovery increases the likelihood of success and shortens development time.

Key takeaways:

  • AstraZeneca and Absci have signed a deal worth approximately $247 million to work on Generative AI-Built Cancer Antibodies, aligning with AstraZeneca's long-term goals of replacing chemotherapy.
  • The partnership aims to use Absci's AI technology for large-scale protein analysis in the search for a workable cancer treatment.
  • AstraZeneca is developing AI-assisted cancer antibodies and has shown in clinical studies that their novel treatment outperforms traditional chemotherapy.
  • Absci's AI development in medicine continues with a recent alliance with Almirall to create and market AI-powered treatments for severe and persistent skin conditions.
View Full Article

Comments (0)

Be the first to comment!